← Eichor
Condition: Residual Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Residual Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT07726602Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT06840262ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreati
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05802394MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · 1 location(s) · University of Illinois at Chicago · NCT05192122Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Ind
Phase N/A · 1 location(s) · Massachusetts Eye and Ear Infirmary · NCT06744296ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Phase 2 · 20 location(s) · UNICANCER · NCT05973864Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Phase 2 · 1 location(s) · UNICANCER · NCT06450314Tessa Jowell BRAIN MATRIX - Platform Study
Phase N/A · 14 location(s) · University of Birmingham · NCT04274283tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Phase 3 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06332274cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
NA · 4 location(s) · Centre Jean Perrin · NCT07178847Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
Phase N/A · 1 location(s) · JaxBio Ltd · NCT06963307Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cer
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT05749887Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
Phase N/A · 1 location(s) · Invitae Corporation · NCT06043921Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in
Phase N/A · 1 location(s) · Oncology Institute of Southern Switzerland · NCT04543799Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Phase N/A · 7 location(s) · Zhujiang Hospital · NCT06157060Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · 356 location(s) · Gilead Sciences · NCT05633654Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cance
NA · 13 location(s) · City of Hope Medical Center · NCT07125729ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NA · 1 location(s) · Hua-Jay J Cherng, MD · NCT06693830
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.